Navigation Links
Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
Date:2/1/2010

Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.

(Vocus) February 1, 2010 -- Astrogenetix is issuing the following statement applauding NASA's commitment to extend the life of the International Space Station (ISS) to 2020 or beyond.

Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:

“We are excited to see such a significant commitment from the Obama Administration and NASA to extend the International Space Station to 2020 or beyond. The ISS National Lab provides us with one of our country’s most unique environments for conducting scientific research. Astrogentix is very proud of our results in discovering the salmonella vaccine during the National Lab Pathfinder missions. The vision outlined today will allow for continued discoveries of important vaccines like MRSA and provide a platform for many more discoveries in the future.”

About Astrogenetix, Incorporated
A subsidiary of Astrotech Corporation (Nasdaq: ASTC), Astrogenetix is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity. The Company offers a turn-key platform for pre-flight sample preparation, flight hardware, mission planning and operations, crew training and certification processes needed within the highly regulated and complex environment of manned space flight.

The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

###

Read the full story at http://www.prweb.com/releases/2010/02/prweb3551324.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
3. Anacor Files Registration Statement for Initial Public Offering
4. IsoTis Files Definitive Proxy Statement
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. Statement on Direct-To-Consumer Genetic Testing
7. Coherent Announces Restatement Related to Stock-Based Compensation
8. XTL Biopharmaceuticals: AGM/EGM Statements
9. Statement from GPhA President and CEO Kathleen Jaeger on FDAs Generic Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement
(Date:1/19/2017)... -- Research and Markets has announced the addition of ... Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" report ... ... projected to reach $15,737 million by 2022 from $6,521 in 2015, ... Omic technologies segment accounted for more than half of ...
(Date:1/19/2017)... Research and Markets ... announced the addition of the "Implantable Biomaterials Market ... report to their offering. Report Highlights: ... analysis on current and future market trends to identify the investment opportunities ... the base numbers Key market trends across the business ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... Island, NY (PRWEB) , ... January 19, 2017 , ... ... at an exponential rate. The tremendous growth is accounted to two main factors. ... the table and the expanding network of vendors supplying FireflySci products all around the ...
Breaking Biology Technology:
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):